for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amicus Therapeutics, Inc.

FOLD.O

Latest Trade

9.73USD

Change

0.17(+1.78%)

Volume

685,781

Today's Range

9.50

 - 

9.74

52 Week Range

8.27

 - 

14.62

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
9.56
Open
9.58
Volume
685,781
3M AVG Volume
73.29
Today's High
9.74
Today's Low
9.50
52 Week High
14.62
52 Week Low
8.27
Shares Out (MIL)
254.63
Market Cap (MIL)
2,492.79
Forward P/E
-6.62
Dividend (Yield %)
--

Next Event

Amicus Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Amicus Therapeutics Q2 Loss Per Share $0.36

Amicus Therapeutics, Catalent Biologics Enter Strategic Partnership For Gene Therapy Development And Manufacturing

Amicus Therapeutics And Brammer Bio Enter Gene Therapy Collaboration

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.

Industry

Biotechnology & Drugs

Contact Info

1 Cedarbrook Dr

+1.609.6622000

http://www.amicusrx.com

Executive Leadership

John F. Crowley

Chairman of the Board and Chief Executive Officer

Bradley L. Campbell

President, Chief Operating Officer, Director

Daphne E. Quimi

Chief Financial Officer

Simon Jordan

Senior Vice President - International

Jill Weimer

Senior Vice President of Discovery Research and Gene Therapy Science

Key Stats

1.67 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.1K

2019(E)

0.2K
EPS (USD)

2016

-1.490

2017

-1.850

2018

-1.880

2019(E)

-1.478
Price To Earnings (TTM)
--
Price To Sales (TTM)
18.97
Price To Book (MRQ)
4.15
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
24.84
LT Debt To Equity (MRQ)
24.84
Return on Investment (TTM)
-55.23
Return on Equity (TTM)
-50.71

Latest News

Amicus sets $315,000 price for new Fabry disease treatment

Amicus Therapeutics <FOLD.O> on Monday set an average price of $315,000 per year for its newly approved Fabry disease treatment, a price it believes is below that of the main existing treatment in the United States.

Amicus sets $315,000 price for new Fabry disease treatment

Amicus Therapeutics priced its new Fabry disease treatment at an average $315,000 per year in the United States, the company said on Monday.

Amicus Therapeutics receives U.S. approval for Fabry disease drug

U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

Amicus Therapeutics receives U.S. approval for Fabry disease drug

U.S. health regulators on Friday approved Amicus Therapeutics' Galafold, the first oral therapy to treat Fabry disease, a rare, sometimes fatal condition in which accumulation of fat damages several organs.

BRIEF-Amicus Therapeutics Reports Q1 Loss Per Share Of $0.28

* AMICUS THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATES

BRIEF-Amicus Therapeutics Prices Underwritten Offering Of Common Stock

* AMICUS THERAPEUTICS PRICES UNDERWRITTEN OFFERING OF COMMON STOCK

BRIEF-Amicus Therapeutics Announces Public Offering Of Common Stock

* AMICUS THERAPEUTICS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK

BRIEF-U.S. FDA Files NDA Under Priority Review For Migalastat

* U.S. FDA FILES NEW DRUG APPLICATION UNDER PRIORITY REVIEW FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE

BRIEF-Amicus Announces Additional Data In Pompe Disease Phase 1/2 Study

* AMICUS THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE DATA IN POMPE DISEASE PHASE 1/2 STUDY AT 14TH ANNUAL WORLDSYMPOSIUM™

BRIEF-Amicus Launches Galafold For Treatment Of Fabry Disease In Spain

* AMICUS THERAPEUTICS LAUNCHES GALAFOLD™ (MIGALASTAT) FOR TREATMENT OF FABRY DISEASE IN SPAIN Source text for Eikon: Further company coverage:

BRIEF-Amicus Therapeutics Expects 2018 Net Cash Spend Of $230 Mln To $260 Mln

* AMICUS THERAPEUTICS PROVIDES FULL-YEAR 2018 STRATEGIC OUTLOOK AND FINANCIAL GUIDANCE

BRIEF-Amicus Therapeutics Submits New Drug Application To U.S. FDA For Migalastat

* AMICUS THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE

BRIEF-Amicus Therapeutics Q3 loss per share $0.69

* Amicus therapeutics announces third quarter 2017 financial results and corporate updates

Swiss Amicus and Brazil's EMS bid for Serbian drugmaker Galenika

Swiss-based drugs company Amicus SRB and Brazilian pharma group EMS SA have both made binding bids for a 93 percent stake in Serbian drugmaker Galenika, Serbia's Economy Ministry said.

Swiss Amicus and Brazil's EMS bid for Serbian drugmaker Galenika

Swiss-based drugs company Amicus SRB and Brazilian pharma group EMS SA have both made binding bids for a 93 percent stake in Serbian drugmaker Galenika, Serbia's Economy Ministry said.

BRIEF-Amicus Therapeutics announces additional positive data in Pompe disease phase 1/2 study at World Muscle Society

* Amicus Therapeutics announces additional positive data in Pompe disease phase 1/2 study at World Muscle Society

BRIEF-U.S. FDA grants fast track designation for Amicus Therapeutics’ migalastat for treatment of Fabry disease

* U.S. FDA grants fast track designation for Amicus Therapeutics’ migalastat for treatment of Fabry disease

BRIEF-Amicus Therapeutics announces approval for Galafold™ for treatment of Fabry disease in Canada

* Amicus Therapeutics Inc announces approval for Galafold™ (Migalastat) for treatment of Fabry disease in Canada

Amicus abandons wound treatment, focus shifts to future trial data

Amicus Therapeutics Inc said on Wednesday it would stop developing its experimental drug for healing wounds related to a rare skin disease, but shares of the company rose as investors appeared to focus on the drug developer's expanding pipeline.

Amicus Therapeutics' wound treatment fails late-stage trial

U.S. drug developer Amicus Therapeutics Inc said on Wednesday its drug to treat wounds failed to meet the main goals of a late-stage clinical trial.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up